Brief: Oncozenge Cancels Planned Patient Study With Bupizenge

Oncozenge AB

12/04/2022 07:07

April 12 (Reuters) - Oncozenge AB  ONCOZ.ST :
    * CANCELS THE PLANNED PATIENT STUDY WITH BUPIZENGE
    * BASED ON NEW INFORMATION, DATA CURRENT CLINICAL
DEVELOPMENT PLAN
WITH EXISTING PRODUCT FORMULATION IS ASSESSED TO CONSTITUTE
POTENTIAL PATIENT SAFETY RISK
    * WILL WORK ON UPDATED PLAN FOR PROJECT AND CO'S POSSIBLE
PATHS
GOING FORWARD

Source text for Eikon:  ID:nWkrbH3Ddv 
Further company coverage:  ONCOZ.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))